Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 26 Melanoma 24 Carcinoma, Renal Cell 16 Stomach Neoplasms 9 Lung Neoplasms 9 Squamous Cell Carcinoma of Head and Neck 6 Carcinoma, Hepatocellular 6 Kidney Neoplasms 5 Brain Neoplasms 5 Urinary Bladder Neoplasms 4 Neoplasms 4 Mesothelioma 4 Adenocarcinoma Of Esophagus 4 Skin Neoplasms 3 Neoplasm Metastasis 3 Head and Neck Neoplasms 3 Colorectal Neoplasms 3 Anus Neoplasms 3 Various Advanced Cancer 2 Prostatic Neoplasms 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Mesothelioma, Malignant 2 Liver Neoplasms 2 Hodgkin Disease 2 Esophageal Neoplasms 2 Colonic Neoplasms 2 Carcinoma 2 Anal Canal Carcinoma 2 Adenocarcinoma 2 von Hippel-Lindau Disease 1

Interventions

relatlimab 1 pembrolizumab 1 lifileucel 1 Vitamin D 1 Temozolomide 1 Paclitaxel 1 Opdualag 1 Nivolumab 1 Ipilimumab 1 Dacarbazine 1 Cholecalciferol 1 Carboplatin 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Melanoma, Cutaneous Malignant × Nivolumab × Clear all

NCT06743126 2026-05-29

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡